A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 Meeting Abstract
| Authors: | Cohen, D. J.; Tabernero, J.; Van Cutsem, E.; Janjigian, Y. Y.; Bang, Y. J.; Qin, S.; Wainberg, Z. A.; Wang, A.; Hawk, N. N.; Shih, C. S.; Bhagia, P.; Shitara, K. |
| Abstract Title: | A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 |
| Meeting Title: | 2022 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2022 Jan 20-22 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-01 |
| Language: | English |
| ACCESSION: | WOS:000770995900357 |
| DOI: | 10.1200/JCO.2022.40.4_suppl.TPS369 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS369 -- Meeting was conducted online as well as in person -- Source: Wos |
